Imaging of glutamate neurotransmitter alterations in Alzheimer's disease. (9th October 2012)

• Record Type: Journal Article
• Authors: Haris, Mohammad; Nath, Kavindra; Cai, Kejia; Singh, Anup; Crescenzi, Rachelle; Kogan, Feliks; Verma, Gaurav; Reddy, Sanjana; Hariharan, Hari; Melhem, Elias R.; Reddy, Ravinder
• Is Part Of: NMR in biomedicine. Volume 26:Number 4(2013:Apr.)
• Page Start: 386
• Page End: 391
• Publication Date: 2012-10-09
• Subjects: Nuclear magnetic resonance -- Periodicals; Magnetic Resonance Spectroscopy -- Periodicals; 574
• DOI: 10.1002/nbm.2875
• Languages: English
• ISSNs: 0952-3480

Abstract

<abstract abstract-type="main"> <title> <x xml:space="preserve">Abstract</x> </title> <p>Glutamate (Glu) is a major excitatory neurotransmitter in the brain and has been shown to decrease in the early stages of Alzheimer's disease (AD). Using a glutamate chemical (amine) exchange saturation transfer (GluCEST) method, we imaged the change in [Glu] in the APP‐PS1 transgenic mouse model of AD at high spatial resolution. Compared with wild‐type controls, AD mice exhibited a notable reduction in GluCEST contrast (~30%) in all areas of the brain. The change in [Glu] was further validated through ¹H MRS. A positive correlation was observed between GluCEST contrast and ¹H MRS‐measured Glu/total creatine ratio. This method potentially provides a novel noninvasive biomarker for the diagnosis of the disease in preclinical stages and enables the development of disease‐modifying therapies for AD. Copyright © 2012 John Wiley &amp; Sons, Ltd.</p> </abstract>